Brokerages forecast that Dare Bioscience Inc (NASDAQ:DARE) will report earnings per share of ($0.24) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Dare Bioscience’s earnings. Dare Bioscience posted earnings of ($1.42) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 83.1%. The business is scheduled to announce its next earnings results on Monday, October 1st.

On average, analysts expect that Dare Bioscience will report full year earnings of ($1.61) per share for the current fiscal year. For the next fiscal year, analysts forecast that the business will post earnings of ($0.79) per share, with EPS estimates ranging from ($0.91) to ($0.67). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Dare Bioscience.

Dare Bioscience (NASDAQ:DARE) last posted its earnings results on Monday, August 13th. The biotechnology company reported ($0.32) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.23) by ($0.09).

Separately, Maxim Group initiated coverage on Dare Bioscience in a report on Friday, August 17th. They set a “buy” rating and a $3.00 price objective for the company.

Shares of NASDAQ DARE traded down $0.01 during midday trading on Thursday, hitting $0.99. 1,110 shares of the company’s stock were exchanged, compared to its average volume of 166,388. Dare Bioscience has a 12-month low of $0.74 and a 12-month high of $3.59. The firm has a market capitalization of $11.42 million, a price-to-earnings ratio of -0.81 and a beta of 2.68.

An institutional investor recently bought a new position in Dare Bioscience stock. CVI Holdings LLC bought a new position in Dare Bioscience Inc (NASDAQ:DARE) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 471,661 shares of the biotechnology company’s stock, valued at approximately $395,000. Dare Bioscience makes up about 0.5% of CVI Holdings LLC’s holdings, making the stock its 22nd biggest position. CVI Holdings LLC owned approximately 4.13% of Dare Bioscience as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 6.73% of the company’s stock.

Dare Bioscience Company Profile

Daré Bioscience, Inc, a clinical-stage biopharmaceutical company, focuses on developing and marketing women's reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product candidates include Ovaprene, a non-hormonal monthly contraceptive; and SST-6007, a topical sildenafil cream for female sexual arousal disorder.

Read More: Google Finance Portfolio Workaround

Get a free copy of the Zacks research report on Dare Bioscience (DARE)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Dare Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dare Bioscience and related companies with's FREE daily email newsletter.